Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss

The same hormone that makes rats less fat is also the focus of a new way to treat diabetes currently being researched. Tripeptide is the name of the medicine in question. It is an antibody that binds to glucagon-like peptide-1 in the blood (GLP-1). This treatment makes people feel less hungry, which lowers their blood sugar levels.

You may have read about how this medicine, in the form of a nasal spray, helped some people lose weight. Because it also stops the body from making the hormone that controls hunger, it can help with the initial weight loss and keep the weight off in the long run.

Even if you use it once a day, it could still help you lose weight in a big way. In addition to helping you control how many calories you eat and how much sugar is in your blood, tripeptide's effects on insulin and glucagon may also help stop your body from making fat. This article tells you about tripeptides and how they might be used to treat type 2 diabetes (T2DM).

Research

Tirzepatide (Mounjaro), a new medicine used to treat Type 2 Diabetes, works well to help people who are overweight lose weight. The amount of weight loss seen in the trial was much higher than that seen before with other FDA-approved drugs, both in terms of the total weight loss and the percentage of weight loss. Experts had checked the data with the help of groups on whom both methods were tested for study purpose.

There were a total of 2,539 people in the study to see the results of this new medicine. Their average weight was 231 pounds, and 95% had a body mass index (BMI) of 38 or more. All of the subjects were white. A body mass index (BMI) of 30 or more means that a person is obese.

During the study, each participant got either a single injection of a placebo or one of three different doses of Tirzepatide (5 mg, 10 mg, or 15 mg). The study went on for 72 weeks in total.

When the highest dose was given, people lost an average of 20.9% of their body weight, about 52 pounds. People who took the 10 mg dose lost 19.5% of their weight, about 49 pounds. Those who took the 5 mg dose lost 15% of their weight, about 35 pounds.

About 4% to 7% of people stopped taking their medicine because it made them feel bad. The most common side effects were stomach problems like nausea, vomiting, and diarrhea.

Clinical trial

The clinical trial was a phase 3 test, the last step before getting permission from the right people in the United States.

These results are a big step forward in the search of effective medicines to fight obesity. When people with obesity took Tirzepatide to treat their obesity, almost nine out of ten lost a lot of weight.

Taking Tirzepatide can have good effects on blood sugar levels and appetite

When a person takes Tirzepatide, the levels of the hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) change. Tirzepatide was the first drug of its kind (GIP). These hormones control how much sugar is in the blood and tell the brain when the stomach is empty.

In May, the FDA said that Tirzepatide could help people with type 2 diabetes control their blood sugar levels. "Mounjaro" is the name of the medicine that is used to treat diabetes.

The Food and Drug Administration (FDA) found that Tirzepatide was more effective than two types of insulin and the injectable GLP-1 receptor agonist semaglutide at lowering blood sugar and helping people with type 2 diabetes lose weight (Ozempic).

There are still questions about how well Tirzepatide works and how much it costs

The fact that no other medications were used as a point of comparison in the most recent research on tripeptide as a treatment for obesity is one of the issues with the study. One of the things that the study requires assistance with is doing this one. Experts consider the possibility that the tripeptide will reveal itself to be the most successful treatment for obesity in general. In that scenario, it needs to be evaluated alongside semaglutide and liraglutide, two other medications that are quite comparable to it. In addition, the pharmaceutical company Novo Nordisk, which is responsible for the production of semaglutide, has provided financial support to Hamdy.

The findings of the most recent clinical research suggest that taking the greatest possible dose of Tirzepatide may have benefits that are comparable to those of bariatric surgery. The findings point to the possibility that this is correct. Let's imagine that the FDA comes to the conclusion that Tirzepatide can be made available to the general population. If that turns out to be the case, the cost of the medication will have a substantial impact on how frequently individuals take it.

How does it affect obesity?

Because obesity frequently triggers the development of additional, more expensive ailments, such as diabetes, high blood pressure, and heart disease, this is a critical issue that requires quick attention. This is due to the fact that obesity is a significant issue that requires careful consideration. As a result of this, experts also focus on new options that can prove effective in controlling obesity.

Conclusion

According to the pricing information that has been made available, the suggested retail price for some of the newest weight reduction medications, such as semaglutide (Wegovy) and liraglutide (Saxenda), is more than $1,300 a month. Both of these medications are marketed under the brand names Wegovy and Saxenda, respectively. Experts do not hope that in the relatively near future, the cost of Tirzepatide will decrease to a point where it can be more manageable. Due to the severe health risks of obesity and the fact that many people have trouble losing weight and keeping it off, there is an urgent need for new ways to treat this problem.